-
-
-
-
-
-
-
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
-
-
-
-
-
-
-
J&J tops first-quarter profit estimates even as Stelara sales plunge
-
-
-
-
-
-
-
Johnson & Johnson (JNJ) PT Raised to $221 at BofA Securities
-
-
-
-
-
-
-
Johnson & Johnson completes $3.05 billion Halda Therapeutics acquisition
-
-
-
-
-
-
-
FDA approves Johnson & Johnson's CAPLYTA for major depressive disorder
-
-
-
-
-
-
-
Jefferies flags Q3 earnings upside for this pharma giant as key drugs outperform
-
-
-
-
-
-
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
1,206,249 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

